p53-dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 6, 2005, Pages 3568-3574

  Grimberg, Adda ^a   Coleman, Carrie M ^a   Burns, Timothy F ^b   Himelstein, Bruce P ^c   Koch, Cameron J ^b   Cohen, Pinchas ^d   El Deiry, Wafik S ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 3; DEXAMETHASONE; DOXORUBICIN; MESSENGER RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; DNA DAMAGE; FEMALE; HYPOXIA; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION; TISSUE SPECIFICITY; TUMOR CELL LINE; ANIMAL; CELL CULTURE; CELL HYPOXIA; CELL LINE; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; HUMAN; LUNG TUMOR; MOUSE MUTANT; PHYSIOLOGY; RADIATION EXPOSURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CELL HYPOXIA; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; DEXAMETHASONE; DNA DAMAGE; DOXORUBICIN; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 21244438392     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1213     Document Type: Article

References (59)

1. Hainaut P, Hollstein M 2000 p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81-137
2. Vousden KH, Prives C 2005 p53 and prognosis: new insights and further complexity. Cell 120:7-10
3. Brooks CL, Gu W 2003 Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15:164-171
4. Fabbro M, Henderson BR 2003 Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 282:59-69
5. Gostissa M, Hofmann TG, Will H, Del Sal G 2003 Regulation of p53 functions: let's meet at the nuclear bodies. Curr Opin Cell Biol 15:351-357
6. Oren M 2003 Decision making by p53: life, death and cancer. Cell Death Differ 10:431-442
7. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B 1999 Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 96:14517-14522
8. Balint EE, Vousden KH 2001 Activation and activities of the p53 tumour suppressor protein. Br J Cancer 85:1813-1823
9. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N 1995 Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649
10. Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, May P, Debuire B, May E 1997 Further characterisation of the p53 responsive element-identification of new candidate genes for trans-activation by p53. Oncogene 14:85-94
11. Grimberg A, Cohen P 2000 The role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 183:1-9
12. Friedlander P, Haupt Y, Prives C, Oren M 1996 A mutant p53 gene that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16:4961-4971
13. Ludwig RL, Bates S, Vousden KH 1996 Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 16:4952-4960
14. Ryan KM, Vousden KH 1998 Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 18:3692-3698
15. Grimberg A, Liu B, Bannerman P, El-Deiry WS, Cohen P 2002 IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int J Oncol 21:327-335
16. Thomas M, Matlashewski G, Pim D, Banks L 1996 Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene 13:265-273
17. Mantovani F, Banks L 2001 The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20:7874-7887
18. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B 1993 WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
19. Burns TF, Bernhard EJ, El-Deiry WS 2001 Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 20:4601-4612
20. Wu GS, El-Deiry WS 1996 Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res 2:623-633
21. Thomas MC, Chiang CM 2005 E6 Oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 17:251-264
22. Coleman C, Grimberg A 2002 Alterations in the expression of insulin-like growth factors and their binding proteins in lung cancer. In: Driscoll B, ed. Methods in molecular medicine: lung cancer. Vol 1. Molecular pathology methods and reviews. Totawa, NJ: The Humana Press Inc.; 167-186
23. Wahl R, Geissler W, Maasch HJ 1985 Comparison of classical Lowry, modified Lowry and a dye-binding assay for the estimation of protein in allergen extracts and influence of different parameters on the modified Lowry assay. Biol Chem Hoppe Seyler 366:979-984
24. Koch CJ 1984 A "thin-film" culturing technique allowing rapid gas-liquid equilibration (6 seconds) with no toxicity to mammalian cells. Radiat Res 97:434-442
25. Koch CJ, Kruuv J 1972 The release of oxygen from polystyrene Petri side dishes. Br J Radiol 45:787-788
26. Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K, Johnson RS 2001 Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 21:3436-3444
27. Gudkov AV, Komarova EA 2003 The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3:117-129
28. Fei P, El-Deiry WS 2003 p53 and radiation responses. Oncogene 22:5774-5783
29. Fei P, Bernhard EJ, El-Deiry WS 2002 Tissue-specific induction of p53 targets in vivo. Cancer Res 62:7316-7327
30. El-Deiry WS 2003 The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22:7486-7495
31. Perry, MC 2001 The chemotherapy source book. 3rd ed. Philadelphia: Lippincott, Williams and Wilkins
32. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T 2002 p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416:560-564
33. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin Jr WG 2003 Chemosensitivity linked to p73 function. Cancer Cell 3:403-410
34. Benard J, Douc-Rasy S, Ahomadegbe JC 2003 TP53 family members and human cancers. Hum Mutat 21:182-191
35. Nunn SE, Peehl DM, Cohen P 1997 Acid-activated insulin-like growth factor binding protein protease activity of Cathepsin D in normal and malignant prostatic epithelial cells and seminal plasma. J Cell Physiol 171:196-204
36. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG 1992 Prostate specific antigen (PSA) is an IGF binding protein (IGFBP-3) protease found in seminal plasma. J Clin Endocrinol Metab 75:1046-1053
37. Grimberg A, Rajah R, Zhao H, Cohen P 1998 The prostatic IGF system: new levels of complexity. In: Takano K, Hizuka N, Takahashi SI, eds. Molecular mechanisms to regulate the activities of insulin-like growth factors. Amsterdam: Elsevier Science B.V.; 205-213
38. Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ, Giaccia AJ 2000 Candidate genes for the hypoxic tumor phenotype. Cancer Res 60:883-887
39. Semenza GL 2000 HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88:1474-1480
40. Huang LE, Bunn HF 2003 Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 278:19575-19578
41. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL 1999 Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res 59:3915-3918
42. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E, Keshet E 1998 Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485-490
43. Chen D, Li M, Luo J, Gu W 2003 Direct interactions between HIF-1α and Mdm2 modulate p53 function. J Biol Chem 278:13595-13598
44. Pan Y, Oprysko PR, Asham AM, Koch CJ, Simon MC 2004 p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment. Oncogene 23:4975-4983
45. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS 2003 Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol Cell Biol 23:359-369
46. Tazuke SI, Mazure NM, Sugawara J, Carland G, Faessen GH, Suen LF, Irwin JC, Powell DR, Giaccia AJ, Giudice LC 1998 Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal hypoxia. Proc Natl Acad Sci USA 95:10188-10193
47. Popovici RM, Lu M, Bhatia S, Faessen GH, Giaccia AJ, Giudice LC 2001 Hypoxia regulates insulin-like growth factor-binding protein 1 in human fetal hepatocytes in primary culture: suggestive molecular mechanisms for in utero fetal growth restriction caused by uteroplacental insufficiency. J Clin Endocrinol Metab 86:2653-2659
48. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B 1992 Definition of a consensus binding site for p53. Nat Genet 1:45-49
49. Hanafusa T, Shinji T, Shiraha H, Nouso K, Iwasaki Y, Yumoto E, Ono T, Koide N 2005 Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation. BMC Cancer 5:9
50. Werner H, Karnieli E, Rauscher FJ, LeRoith D 1996 Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93:8318-8323
51. Zhang L, Zhan Q, Zhan S, Kashanchi F, Fornace Jr AJ, Seth P, Helman LJ 1998 p53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. DNA Cell Biol 17:125-131
52. Ohlsson C, Kley N, Werner H, LeRoith D 1998 p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology 139:1101-1107
53. Prisco M, Hongo A, Rizzo MG, Sacchi A, Baserga R 1997 The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol Cell Biol 17:1084-1092
54. Grimberg A 2003 Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther 2:630-635
55. Oh Y, Muller HL, Lamson G, Rosenfeld RG 1993 Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268:14964-14971
56. Oh Y, Muller HL, Pham H, Rosenfeld RG 1993 Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268:26045-26048
57. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P 2000 Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-α regulate transcriptional signaling and apoptosis. J Biol Chem 275:33607-33613
58. Grimberg A 2000 p53 and IGFBP-3: apoptosis and cancer protection. Mol Genet Metab 70:85-98
59. Sherr CJ 2004 Principles of tumor suppression. Cell 116:235-246